Infectious Diseases | |
|---|---|
| Study Name | Principal Investigator |
| APT.DFI.001 – A phase 2b randomized, parallel group, double-blind, placebo-controlled, repeat dose, multi-site study investigating the safety, tolerability, and efficacy of personalized phage treatment and standard of care antimicrobials for subjects with diabetic foot osteomyelitis due to S. aureus. Read more. |
Suraj Saggar, DO |
| 000422 – REBYOTATM for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study. Read more. |
Suraj Saggar, DO |
| LBx-2001 – A Two-Part, Phase 2, Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug Resistant Escherichia coli (a.k.a. ELIMINATE trial). Read more. |
Suraj Saggar, DO |
